📰 **GSK: Japan's MHLW Expands Eligible Population For Arexvy **

(RTTNews) - GSK plc (GSK, GSK.L) announced that Japan's Ministry of Health, Labour and Welfare has expanded the eligible population for RSV vaccine, Arexvy, to include adults aged 18 to 49 years at increased risk for RSV disease. GSK's RSV vaccine was previously approved in Japan...

🔗 https://www.nasdaq.com/articles/gsk-japans-mhlw-expands-eligible-population-arexvy

#markets #news